Peptide receptor radionuclide therapy (PRRT) for GEP-NETs

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):867-81. doi: 10.1016/j.bpg.2013.01.004.


Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). (90)Y-DOTATOC and (177)Lu-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response rates (about 15-35%). The side effects of this therapy are few and mild. However, amino acids should be used for kidney protection, especially during infusion of (90)Y-DOTATOC. Options to improve PRRT may include combinations of radioactive labelled somatostatin analogues and the use of radiosensitising drugs combined with PRRT. Other therapeutic applications of PRRT may include intra-arterial administration, neo-adjuvant treatment and additional PRRT cycles in patients with progressive disease, who have benefited from initial therapy. Considering the mild side-effects, PRRT may well become the first-line therapy in patients with metastasised or inoperable GEP-NETs if more widespread use of PRRT can be accomplished.

MeSH terms

  • Heterocyclic Compounds / therapeutic use
  • Heterocyclic Compounds, 1-Ring / therapeutic use
  • Humans
  • Intestinal Neoplasms / metabolism
  • Intestinal Neoplasms / radiotherapy*
  • Neuroendocrine Tumors / metabolism
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives
  • Octreotide / therapeutic use
  • Organometallic Compounds / therapeutic use
  • Peptides, Cyclic / therapeutic use
  • Radiopharmaceuticals / therapeutic use*
  • Receptors, Somatostatin / metabolism
  • Retreatment
  • Somatostatin / analogs & derivatives*
  • Somatostatin / metabolism
  • Stomach Neoplasms / metabolism
  • Stomach Neoplasms / radiotherapy*
  • Yttrium Radioisotopes / therapeutic use


  • Heterocyclic Compounds
  • Heterocyclic Compounds, 1-Ring
  • Organometallic Compounds
  • Peptides, Cyclic
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Yttrium Radioisotopes
  • yttrium 90-DOTA-lanreotide
  • Somatostatin
  • lutetium Lu 177 dotatate
  • Octreotide
  • Edotreotide